Anticancer therapeutic agent using peg10 gene associated with CDK4 / 6 inhibitor resistance development and aso
PEG10 ASOs, used in conjunction with CDK4/6 inhibitors, address resistance issues by targeting PEG10 and EMT pathways, enhancing treatment efficacy for CDK4/6 inhibitor-resistant breast cancer.
Patent Information
- Application Number
- PCT/KR2023/012180
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2023-08-17
- Publication Date
- 2024-11-07
AI Technical Summary
CDK4/6 inhibitors, a new treatment for breast cancer, face resistance issues, necessitating a solution to overcome drug resistance and enhance treatment efficacy.
The use of PEG10-specific anti-sense oligonucleotides (ASOs) that inhibit PEG10 expression, combined with CDK4/6 inhibitors, to target and overcome resistance mechanisms in cancer cells, including the EMT pathway, thereby enhancing treatment effectiveness.
The PEG10 ASO effectively inhibits PEG10 expression and associated EMT mechanisms, improving the efficacy of CDK4/6 inhibitors in resistant cancer cells, as demonstrated by increased anticancer activity and tumor growth inhibition in xenograft models.
Smart Images

Figure KR2023012180_07112024_PF_FP_ABST
Abstract
Description
Anticancer treatment using PEG10 gene and ASO associated with CDK4 / 6 inhibitor resistance development
[0001] This relates to anticancer treatment using PEG10 and ASO, genes associated with the development of CDK4 / 6 inhibitor resistance.
[0002] Breast cancer is the most common cancer in women, accounting for 20.6% of all cancers in women. The number of breast cancer patients in Korea is steadily increasing, and the rate of increase in Korea's breast cancer rate is the highest in the world.
[0003] Breast cancer can be classified as HR-positive, HER2-positive, or triple-negative, depending on the expression of hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2). HR-positive breast cancer is the most common type, accounting for approximately 70% of all breast cancers.
[0004] Hormonal therapy and chemotherapy are currently used to treat breast cancer. Recently, CDK4 / 6 inhibitors, a novel therapeutic agent with a novel mechanism of action, have been developed and are being used in the treatment of breast cancer. However, even with effective drugs, drug resistance eventually develops, necessitating treatments that can overcome this resistance.
[0005] One aspect is to provide an antisense oligonucleotide (ASO) comprising any one polynucleotide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5 capable of inhibiting the expression of PEG10 (Paternally Expressed 10).
[0006] Another aspect is to provide a pharmaceutical composition for treating cancer comprising an expression or activity inhibitor of PEG10 (Paternally Expressed 10) as an active ingredient.
[0007] Another aspect provides a method of treating cancer comprising administering to a subject in need thereof an effective amount of an inhibitor of expression or activity of PEG10 (Paternally Expressed 10).
[0008] Another aspect provides the use of an inhibitor of expression or activity of PEG10 (Paternally Expressed 10) for the manufacture of a pharmaceutical preparation for treating cancer.
[0009] Another aspect is to provide a composition for diagnosing cancer resistant to a CDK4 / 6 inhibitor comprising an agent capable of measuring the expression or activity of PEG10.
[0010] Another aspect provides a method of diagnosing a cancer resistant to a CDK4 / 6 inhibitor, comprising the step of measuring the expression or activity of PEG10 from a sample isolated from the subject.
[0011] Another aspect provides the use of inhibitors of expression or activity of PEG10 (Paternally Expressed 10) for diagnosing cancers resistant to CDK4 / 6 inhibitors.
[0012] One aspect provides an antisense oligonucleotide (ASO) comprising any one polynucleotide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5 capable of inhibiting the expression of PEG10 (Paternally Expressed 10).
[0013] The term "PEG10 (Paternally Expressed 10)" used herein refers to a gene known to be involved in placental formation and is derived from a retrotransposon belonging to the Ty3 / Gypsy family. Recent studies have shown that it plays a crucial role in tumor growth in various cancers, including liver, lung, and prostate cancers.
[0014] As used herein, the term "antisense oligonucleotide" or "antisense oligonucleotide (ASO)" refers to a drug that is a single-stranded oligonucleotide that binds to target pre-mRNA or mRNA and regulates target expression through methods such as target degradation, isoform switching, and translation inhibition. As a sequence-based drug, it is characterized by high selectivity for targets with genetic mutations. It is similar to siRNA, but has the advantage of being more chemically modified. Chemically modified ASOs include gapmer ASO, non-degradable ASO, and PMO (Phosphorodiamidatemopholino). The ASO may be used to mean all nucleosides covalently linked to each other through an internucleotide linker, such as naturally occurring nucleosides, or oligomers or polymers of modified forms thereof.
[0015] In this specification, the term "siRNA (short interfering RNA, silencing RNA)" refers to a short strand of RNA consisting of 21 to 23 nucleotides, which interferes with gene expression by suppressing the production of a specific protein.
[0016] As used herein, the term "Gapmer ASO" or "gapmer ASO" refers to a single-stranded oligonucleotide consisting of 16 to 24 mer, which degrades target mRNA by RNAse H. Structurally, several mer of DNA modified with PS (phosphodiester) is positioned in the middle of the oligomer, and several mer of nucleotides modified with PS / 2'-O-MOE (2'-O-methoxyethyl) or PS / 2'-O-ME (2'-O-Methyl) are positioned at each end. When an ASO with such modification binds to a target mRNA with a complementary base sequence, it is recognized as an abnormal combination of DNA and RNA, which calls in RNAse H, and cleaves only the PS-modified position in the middle, thereby eliminating the target mRNA.
[0017] A gapmer may be constructed with the general formula 5'-ABC-3', wherein (i) region B is a contiguous sequence of at least 6 DNA units capable of recruiting RNase; (ii) region A is a first wing sequence of 1 to 10 nucleotides, wherein the first wing sequence comprises one or more nucleotide analogues and optionally one or more DNA units, wherein at least one nucleotide analogue is located at the 3' end of A; and (iii) region C is a second wing sequence of 1 to 10 nucleotides, wherein the second wing sequence comprises one or more nucleotide analogues and optionally one or more DNA units, wherein at least one nucleotide analogue may be located at the 5' end of C.
[0018] The above nucleotide analogue or analogues are high affinity analogues and may be 2'-sugar modified nucleosides independently selected from the group consisting of locked nucleic acid (LNA); 2'-0-alkyl-RNA; 2'-amino-DNA; 2'-fluoro-DNA; arabino nucleic acid (ANA); 2'-fluoro-ANA, hexitol nucleic acid (HNA), intercalating nucleic acid (INA), constrained ethyl nucleoside (cEt), 2'-0-methyl nucleic acid (2'-OMe), 2'-0-methoxyethyl nucleic acid (2'-MOE), and any combination thereof.
[0019] The above nucleotide analogue or analogues may comprise a bicyclic sugar.
[0020] The above-described bicyclic sugar may be, but is not limited to, cEt, 2',4'-constrained 2'-0-methoxyethyl (cMOE), LNA, α-L-LNA, β 2'-0,4'-C-ethylene-crosslinked nucleic acid (ENA), amino-LNA, oxy-LNA, or thio-LNA.
[0021] Preferably, the ASO may be a gapmer ASO.
[0022]
[0023] In one specific embodiment, the ASO may be 8 to 50 nucleotides in length. Preferably, the ASO may be 8 to 45 nucleotides. More preferably, the ASO may be 8 to 40 nucleotides. More preferably, the ASO may be 9 to 40 nucleotides. More preferably, the ASO may be 9 to 35 nucleotides. More preferably, the ASO may be 9 to 30 nucleotides. More preferably, the ASO may be 10 to 30 nucleotides. More preferably, the ASO may be 11 to 29 nucleotides. More preferably, the ASO may be 12 to 28 nucleotides. More preferably, the ASO may be 13 to 27 nucleotides. More preferably, the ASO may be 14 to 26 nucleotides. More preferably, the ASO may be 15 to 25 nucleotides. More preferably, the ASO may be 16 to 24 nucleotides. More preferably, the ASO may be 17 to 23 nucleotides. More preferably, the ASO may be 18 to 22 nucleotides. More preferably, the ASO may be 19 to 21 nucleotides or 20 nucleotides.
[0024] In one specific example, the ASO may be complementary to PEG10. Preferably, the ASO may be a 10 nucleotide sequence excluding the 5 nucleotides at both ends, and PEG10 may be complementarily bound. In the present specification, the ASO may include at least one, two, three, four, five, six, or seven mispatches with respect to the target gene sequence.
[0025] The ASO that complementarily binds to the above PEG10 may bind to a nucleotide sequence of 4500 to 4600, 12050 to 12100, 12150 to 12200, 12220 to 12300 or 14500 to 14600 of the PEG10 genome sequence (e.g., a continuous nucleotide sequence).
[0026] In one specific example, the ASO may be capable of inhibiting a protein associated with the Epithelial-to-Mesenchymal Transition (EMT) mechanism.
[0027] As used herein, the term "epithelial-to-mesenchymal transition (EMT)" refers to the process by which epithelial cells transform into cells with metastatic and invasive capabilities. It is involved in fundamental morphological development, including the development of tissues and organs during embryonic development, and is also implicated in wound healing and the development and progression of cancer in adults.
[0028] In one specific example, the ASO may induce activation of the genes or proteins of SIAH1 and p21. The activation of the genes or proteins of SIAH1 and p21 may induce inhibition of EMT-related mechanisms.
[0029]
[0030] Another aspect provides a pharmaceutical composition for treating cancer comprising an expression or activity inhibitor of PEG10 (Paternally Expressed 10) as an active ingredient.
[0031] Another aspect provides a method of treating cancer comprising administering to a subject in need thereof an effective amount of an inhibitor of expression or activity of PEG10 (Paternally Expressed 10).
[0032] Another aspect provides the use of an inhibitor of expression or activity of PEG10 (Paternally Expressed 10) for the manufacture of a pharmaceutical preparation for treating cancer.
[0033] Another aspect provides a method of treating or preventing breast cancer in a subject in need thereof, comprising administering to the subject a composition comprising the ASO.
[0034] The inhibitor may be any one selected from the group consisting of an antisense oligonucleotide (ASO), a small hairpin RNA, a small interfering RNA (siRNA), and a ribozyme that complementarily binds to the gene of PEG10, but is not limited thereto.
[0035] The above antisense oligonucleotide may comprise any one polynucleotide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5.
[0036] Additionally, the inhibitor may be any one selected from the group consisting of, but not limited to, peptides, peptide mimetics, substrate analogs, aptamers, and antibodies that bind to PEG10 proteins.
[0037] As used herein, the term "antibody" includes an immunoglobulin molecule that immunologically reactives with a specific antigen, and includes polyclonal antibodies, monoclonal antibodies, and functional fragments thereof. The term may also include forms produced by genetic engineering, such as chimeric antibodies (e.g., humanized murine antibodies) and heterologous antibodies (e.g., bispecific antibodies). Among these, monoclonal antibodies are highly specific antibodies directed against a single antigenic site (epitope), and unlike polyclonal antibodies that include different antibodies directed against different epitopes, monoclonal antibodies are directed against only a single epitope on an antigen, making quality control as a therapeutic agent easy. The above antibody comprises a variable region of a heavy chain and / or a light chain constituting an immunoglobulin molecule, and the variable region may include a portion forming an antigen-binding site of the antibody molecule as its primary structure. The antibody is not limited thereto as long as it exhibits the same effect as an anti-PEG10 antibody.
[0038] As used herein, the term "cancer" refers to a physiological condition in animals that is typically characterized by abnormal or uncontrolled cell growth. Cancer and cancer pathology may be associated with, for example, metastasis, interference with normally functioning surrounding cells, release of cytokines or other secreted products at abnormal levels, suppression or enhancement of inflammatory or immunological responses, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
[0039] The above cancer may be a solid cancer or a blood cancer.
[0040] The above solid cancer may be selected from the group consisting of breast cancer, colon cancer, head and neck cancer, lung cancer, stomach cancer, skin cancer, colon cancer, prostate cancer, bladder cancer, kidney cancer, rectal cancer, thyroid cancer, liver cancer, cervical cancer, endometrial cancer, choriocarcinoma, skin cancer, rectal cancer, anal cancer, urethral cancer, ovarian cancer, esophageal cancer, gallbladder cancer, testicular cancer, brain cancer, bone metastasis cancer, glioma, malignant melanoma, and pancreatic cancer, but is not limited thereto.
[0041] In one specific example, the cancer may be a CDK (Cyclin Dependent Kinase) 4 / 6 inhibitor-resistant cancer.
[0042] As used herein, the term "resistance" refers to a weakening or loss of drug efficacy during treatment of cancer patients with anticancer drugs. This may be due to the reduced therapeutic effect of anticancer drugs in cancer cells that have developed drug resistance, resulting in reduced efficacy with repeated administration or dosing.
[0043] The term “sensitivity” as used herein refers to the degree to which cancer cells respond to an anticancer agent.
[0044] In one specific example, the cancer may be CDK4 / 6 inhibitor-resistant breast cancer.
[0045] The term "breast cancer" herein includes, without limitation, all malignant tumors that occur in the breast, and may refer to abnormal tissue that continues to grow in the breast or spreads to other organs. Depending on the location of occurrence, breast cancer is divided into cancer that occurs in parenchymal tissues such as ducts and lobules, and cancer that occurs in other stromal tissues. Ductal and lobular cancers can be further divided into invasive and non-invasive types depending on the extent to which cancer cells have spread to the surrounding area. In addition, breast cancer can be divided into HR-positive breast cancer, HER2-overexpressing breast cancer, and triple-negative breast cancer based on biological characteristics.
[0046] The term "prevention" as used herein collectively refers to partially or completely delaying or preventing the onset or recurrence of a disease, disorder, or its secondary symptoms, preventing the acquisition or reacquisition of a disease or disorder, or reducing the risk of acquiring a disease or disorder. The above prevention refers to any act of inhibiting or delaying the onset of cancer or a cancer-related disease, disorder, or symptom by administering a composition according to the present invention.
[0047] As used herein, the term “treatment” refers to any action by which a disease, disorder, or its accompanying symptoms are improved or beneficially altered.
[0048] In one specific example, the pharmaceutical composition may be formulated as a preparation selected from the group consisting of tablets, soft or hard capsules, pills, powders, suspensions, syrups, injections, and granules.
[0049] The pharmaceutical composition may be administered orally or parenterally. The pharmaceutical composition can be administered parenterally for clinical use and can be used in the form of a general pharmaceutical formulation. Parenteral administration may refer to administration via routes other than oral administration, such as rectal, intravenous, peritoneal, intramuscular, intraarterial, transdermal, nasal, inhalational, ocular, and subcutaneous.
[0050] In one embodiment, the pharmaceutical composition may be for oral or parenteral administration.
[0051] The pharmaceutical composition may contain conventional fillers, bulking agents, binders, disintegrants, anticoagulants, lubricants, wetting agents, pH regulators, nutrients, vitamins, electrolytes, alginic acid and its salts, pectic acid and its salts, protective colloids, glycerin, flavorings, emulsifiers or preservatives.
[0052] The pharmaceutical composition may comprise a pharmaceutically acceptable carrier, examples of which include at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, and saline solution.
[0053] The formulation of the pharmaceutical composition may vary depending on the method of use, and may be formulated using methods well known in the art to which the present invention pertains so as to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
[0054] Formulations for oral administration include tablets, soft or hard capsules, pills, powders, suspensions, syrups, injections, and granules, and these formulations can be manufactured by mixing one or more excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Formulations for parenteral administration can be creams, lotions, ointments, pastes, aerosols, fluid extracts, elixirs, instillations, sachets, patches, or injections, etc. Furthermore, the formulations can be preferably manufactured according to each disease or ingredient using a method disclosed as an appropriate method in the relevant technical field.
[0055] According to one specific example, the composition can inhibit the growth of cancer cells and induce apoptosis.
[0056] The pharmaceutical composition may vary depending on various factors including the activity of the specific compound used, age, body weight, general health, sex, diet, administration time, administration route, excretion rate, drug combination, and severity of the specific disease to be prevented or treated, and the dosage of the pharmaceutical composition may vary depending on the patient's condition, body weight, degree of disease, drug form, administration route, and period, but may be appropriately selected by those skilled in the art, and may be administered at 0.0001 to 500 mg / kg or 0.001 to 500 mg / kg per day. The dosage may be administered once a day or divided into several times. The dosage does not limit the scope of the present invention in any way.
[0057]
[0058] In one specific example, the composition may be capable of being administered in combination with an anticancer agent.
[0059] The above anticancer agent may be at least one selected from the group consisting of chemotherapeutic agents, targeted anticancer agents, immunotherapeutic agents, CDK4 / 6 inhibitors, and combinations thereof, but is not limited thereto.
[0060] As used herein, the term "chemotherapeutic agent" is also referred to as an antitumor drug or cytotoxic agent. It is a general term for drugs that exhibit anticancer activity primarily by directly acting on DNA to block DNA replication, transcription, and translation processes, interfering with the synthesis of nucleic acid precursors in metabolic pathways, and inhibiting cell division. These antitumor drugs exhibit cytotoxicity not only on tumor cells but also on normal cells. Chemotherapeutic agents can be used for maintenance therapy. Furthermore, the term "maintenance therapy" as used herein refers to a treatment method implemented to prevent or delay cancer recurrence by treating cancer with drugs after initial anticancer treatment.
[0061] In one specific example, the chemotherapeutic agent may be any one selected from the group consisting of mechlorethamine, chlorambucil, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine, procarbazine, busulfan, streptozocin, carmustine, lomustine, dacarbazine, cisplatin, carboplatin, oxaliplatin, docetaxel, velvan, oncovin, navelbine, 5-fluorouracil, capecitabine, cytarabine, gemcitabine, fludarabine, methotrexate, pemetrexed, mercaptopurine, hycamtin, camptosa, bepecid, paclitaxel, bleosein, adriamycin, and cerubidine, but is not limited thereto.
[0062] The term "immuno-oncology agent" in this specification refers to a substance that inhibits the activity of immune checkpoint proteins that suppress the differentiation, proliferation, and activity of immune cells, and is known to eliminate cancer cells by preventing cancer cells from exercising their ability to evade the immune system.
[0063] The above-mentioned immuno-oncology agent may be any one selected from the group consisting of anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-B7-H4 antibody, anti-HVEM antibody, anti-TIM3 antibody, anti-GAL9 antibody, anti-LAG3 antibody, anti-VISTA antibody, anti-KIR antibody, anti-BTLA antibody, and anti-TIGIT antibody, but is not limited thereto.
[0064] As used herein, the term "targeted anticancer agent" refers to a drug that selectively attacks cancer cells by targeting specific parts of the cancer cell that differ from normal cells. It is known to inhibit cancer cell proliferation or survival by blocking specific parts of the cell surface involved in signaling or protein regulation processes necessary for cell growth, or by blocking specific signaling processes within the cell.
[0065] The targeted anticancer drugs include abciximab, adalimumab, basiliximab, bezlotoxumab, canakinumab, daclizumab, denosumab, efalizumab, golimumab, inflectra, natalizumab, and olaratumab. It may be any one selected from the group consisting of omalizumab, palipizumab, panitumumab, trastuzumab, pertuzumab, cetuximab, rituximab, tocilizumab, secukinumab, ustekinumab, bevacizumab, avelumab, CDNs, SB11285, and DMXAA, but is not limited thereto.
[0066] As used herein, the term "cyclin-dependent protein kinase" or "CDK (cyclin-dependent kinase)" refers to a kinase that functions to regulate the cell cycle. It can regulate cell division and proliferation, and among the CDK family, CDK4 and CDK6 are responsible for regulating the process of progression from the G1 phase to the S phase of the cell cycle by phosphorylating the cyclin protein D1 to increase its activity.
[0067] The CDK4 / 6 inhibitor that inhibits the above CDK4 / 6 can inhibit both CDK4 and CDK6, and can be used without limitation as long as it is a drug that blocks the formation of the CDK4 / 6-cyclin D1 complex and stops cell division.
[0068] The CDK4 / 6 inhibitor may be, but is not limited to, palbociclib, ribociclib, abemaciclib, and trilaciclib or a pharmaceutically acceptable salt thereof.
[0069] Preferably, the anticancer agent may be palbociclib.
[0070] As used herein, the terms "combination therapy," "combination administration," or "in combination" refer to any form of simultaneous or concurrent treatment using at least two separate anticancer agents and anticancer adjuvants. The components of the combination therapy may be administered simultaneously, sequentially, or in any order. The components may be administered in different dosages, at different frequencies, or via different routes, as appropriate.
[0071] Specifically, the combination administration may be by administering PEG10 ASO and the anticancer agent simultaneously, or by administering PEG10 ASO and then administering the anticancer agent. The combination therapy according to the present invention may be defined as providing a synergistic effect if the efficacy, as measured by, for example, the degree of response, the rate of response, the time until disease progression, or the duration of survival, is therapeutically superior to the efficacy that can be obtained by administering one or the other of the components of the combination therapy at the usual dose. For example, the efficacy of the combination therapy is synergistic if the efficacy is therapeutically superior to the efficacy obtained by using each of the above alone. In particular, a synergistic effect is considered to exist if the usual dose of PEG10 ASO and the anticancer agent can be reduced without compromising one or more of the degree of response, the rate of response, the time until disease progression, and the duration of the response, and in particular without compromising the duration of the response, and with reduced and / or fewer problematic side effects than when each component is used at the usual dose.
[0072] The term "administered simultaneously" as used herein is not particularly limited and means that the components of the combination therapy are administered substantially simultaneously, for example, as a mixture or in an immediately subsequent sequence.
[0073] The term "administered sequentially" as used herein is not particularly limited and means that the components of the combination therapy are administered not simultaneously, but one after another or in clusters with a specific time interval between administrations. The time intervals may be the same or different between the administrations of each of the components of the combination therapy, and may be selected, for example, from the range of 2 minutes to 96 hours, 1 day to 7 days, or 1 week, 2 weeks, or 3 weeks. Typically, the time interval between administrations may range from several minutes to several hours, for example, from 2 minutes to 72 hours, from 30 minutes to 24 hours, or from 1 to 12 hours. Additional examples include time intervals ranging from 24 to 96 hours, from 12 to 36 hours, from 8 to 24 hours, and from 6 to 12 hours.
[0074]
[0075] In one specific example, the subject may be an individual suffering from cancer. The subject may also be a mammal, preferably a human.
[0076] In one specific embodiment, the PEG10 ASO can be administered to a mammal, including a human, by various routes. The route of administration can be any route commonly used, for example, intratumorally, intraarterially, intravenously, intravascularly, intrapleurally, intraperitoneally, intratracheally, intrathecally, intramuscularly, endoscopically, intralesionally, percutaneously, subcutaneously, regionally, stereotactically, orally, by direct injection or perfusion, specifically, orally, intravenously, or subcutaneously.
[0077] The above PEG10 ASO can be administered to a subject in various ways and amounts depending on the patient's condition and the presence or absence of side effects, and the optimal administration method, dosage, and administration frequency can be selected within an appropriate range by a person skilled in the art. In addition, in addition to the above-mentioned effective ingredient, it can be administered in combination with other drugs known to have therapeutic effects on cancer (e.g., the anticancer agent described above) or physiologically active substances, or can be formulated in the form of a combination preparation with other drugs.
[0078]
[0079] Another aspect provides a composition for diagnosing cancer resistant to a CDK4 / 6 inhibitor comprising an agent capable of measuring the expression or activity of PEG10.
[0080] A method for diagnosing cancer resistant to a CDK4 / 6 inhibitor is provided, comprising the step of measuring the expression or activity of PEG10 from a sample isolated from the subject.
[0081] Provided are uses of inhibitors of expression or activity of PEG10 (Paternally Expressed 10) for diagnosing cancer resistant to CDK4 / 6 inhibitors.
[0082] The term “diagnosis” as used herein means confirming the presence or characteristics of a pathological condition.
[0083] The term "biomarker" may also be used as a diagnostic marker, and refers to a substance that can diagnose the development of cancer resistant to CDK4 / 6 inhibitors in a biological sample. It may include organic biomolecules such as polypeptides or nucleic acids (e.g., mRNA, etc.), lipids, glycolipids, glycoproteins, or sugars (e.g., monosaccharides, disaccharides, oligosaccharides, etc.), which show an increase in PEG10 in a biological sample collected from a cancer patient resistant to CDK4 / 6 inhibitors compared to a biological sample obtained from a normal individual. Preferably, the biomarker may be PEG10.
[0084] Measurement of the expression or activity level of the above PEG10 protein is a process of confirming the presence and expression level of PEG10 in a biological sample of an individual to diagnose cancer resistant to CDK4 / 6 inhibitors, and confirms the amount of the protein using a molecule that specifically binds to the protein.
[0085] The agent capable of measuring the expression level of the above PEG10 protein may be, but is not limited to, a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a ligand, a PNA (Peptide nucleic acid), an aptamer, or a nanoparticle that specifically binds to the above protein.
[0086] Analytical methods for this purpose include, but are not limited to, Western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunoprecipitation assay, immunohistochemical analysis, complement fixation assay, fluorescence activated cell sorter (FACS), or protein chip.
[0087] Measurement of the expression level of the gene encoding the above PEG10 protein is a process of confirming the presence and expression level of the PEG10 gene in a biological sample of an individual to diagnose cancer resistant to CDK4 / 6 inhibitors, and confirms the amount of the gene using a molecule that specifically binds to the gene.
[0088] The agent capable of measuring the expression level of the gene encoding the above PEG10 protein may be, but is not limited to, a primer pair, a probe, or an antisense nucleotide that specifically binds to the above gene.
[0089] Analytical methods for this include, but are not limited to, reverse transcriptase-polymerase chain reaction (RT-PCR), real-time polymerase chain reaction, RNase protection assay (RPA), Northern blotting, and DNA chips.
[0090] The term "biological sample" refers to any sample obtained from an individual from which the expression level of the PEG10 protein or the gene encoding it can be measured. The biological sample may be prepared by processing using methods commonly used in the art.
[0091] According to the PEG10 ASO according to the aspect, there is an effect of improving CDK4 / 6 inhibitor resistance through inhibition of PEG10 and EMT mechanism associated with CDK4 / 6 inhibitor-resistant cancer, and when PEG10 ASO and CDK4 / 6 inhibitor are used together, the anticancer efficacy is increased, so it can be usefully used in treating CDK4 / 6-resistant cancer.
[0092] Figure 1 shows the results of mRNA microarray performed on palbociclib-sensitive breast cancer cell lines and palbociclib-resistant breast cancer cell lines.
[0093] Figure 2 shows the expression of PEG10 and EMT-related proteins confirmed by western blot in a palbociclib-resistant cell line.
[0094] Figure 3 shows the expression of EMT-related proteins confirmed by western blot in palbociclib-sensitive hormone receptor-positive breast cancer cells transfected with a PEG10 overexpression plasmid.
[0095] Figure 4 shows the results of MTT assay to confirm the resistance to palbociclib in palbociclib-sensitive hormone receptor-positive breast cancer cells transfected with a PEG10 overexpression plasmid.
[0096] Figure 5 shows the expression of EMT-related proteins confirmed by western blot in palbociclib-resistant cells treated with PEG10 siRNA.
[0097] Figure 6 shows the degree of overcoming resistance to palbociclib in palbociclib-resistant cells administered with a combination of PEG10 siRNA and palbociclib, as confirmed by MTT assay.
[0098] Figure 7 shows the degree of inhibition of ASO 1 to ASO 5 by PEG10 in the MCF7-PR cell line confirmed by western blot.
[0099] Figure 8 shows the degree of inhibition of ASO 1, 3, and 4 by PEG10 in the MCF7-PR cell line confirmed by western blot.
[0100] Figure 9 shows the degree of PEG10 inhibition of ASO 2 and ASO 5 in the MCF7-PR cell line confirmed by western blot.
[0101] Figure 10 shows the degree of inhibition of ASO 1, 3, and 4 by PEG10 in the MCF7-PR cell line, as measured by mRNA expression levels.
[0102] Figure 11 shows the degree of inhibition of ASO 3 and ASO 4 by PEG10 in the MCF7-PR cell line confirmed by western blot.
[0103] Figure 12 shows the degree of inhibition of ASO 3 and ASO 4 by PEG10 in the MCF7-PR cell line as determined by mRNA expression level.
[0104] Figure 13 shows the degree of inhibition of ASO 3 and ASO 4 by PEG10 in the T47D-PR cell line using western blot.
[0105] Figure 14 shows the degree of inhibition of PEG10 at low concentrations (100 nmol) and high concentrations (500 nmol) of ASO 4 using western blot in PC3, a prostate cancer cell line.
[0106] Figure 15 shows the expression of EMT-related proteins confirmed by western blot in palbociclib-resistant cells treated with PEG10 ASO.
[0107] Figure 16 shows the results of a CO-IP assay performed in the MCF7-PR cell line.
[0108] Figure 17 shows that the EMT signaling pathway was inhibited in MCF7-PR and T47D-PR cell lines transduced with SIAH1 and p21 overexpression plasmids, as confirmed by western blot.
[0109] Figure 18 shows the effect on cell cycle control confirmed by western blot in a CDK4 / 6 inhibitor-resistant cell line transduced with a p21 overexpression plasmid.
[0110] Figure 19 shows the cancer growth inhibition effect confirmed in a CDK4 / 6 inhibitor-resistant xenograft model.
[0111] Figure 20 shows the tumor tissue of a CDK4 / 6 inhibitor-resistant xenograft model immunochemically stained to confirm the proliferation marker Ki67.
[0112] Hereinafter, preferred embodiments are presented to aid understanding of the present invention. However, the following embodiments are provided solely to facilitate a better understanding of the present invention and are not intended to limit the scope of the present invention. The embodiments are susceptible to various modifications, and thus the embodiments are not limited to the embodiments disclosed below and may be implemented in various forms.
[0113]
[0114] Example 1. Preparation of PEG10 Gapmer ASO
[0115] To produce Gapmer ASO targeting PEG10 (Paternally Expressed 10), five ASO sequences containing 10 consecutive base sequences within the PEG10 coding sequence were randomly selected. After designing ASOs using the above five sequences to target PEG10, phosphorothioate and 2'-O-methyl groups were added to both ends of each sequence to increase the intracellular uptake and stability of the ASO. PEG10 Gapmer ASOs produced by the above method are shown in Table 1.
[0116] No.Sequence (5'→3')Gapmer ASO 1ACUUC TGTGGGGATG GAGGC (SEQ ID NO: 1)Gapmer ASO 2GUUGU TGTTGTTGTT GGGGG (SEQ ID NO: 2)Gapmer ASO 3AGCUC GTCCCTTCTT CGUUC (SEQ ID NO: 3)Gapmer ASO 4UUUGG TGCTTTAGGA UGUGU (SEQ ID NO: 4)Gapmer ASO 5AGUUA GAAGGAGGGG UAGGG (SEQ ID NO: 5)Gapmer ASO controlCCUUC CCTGAAGGTT CCUCC (SEQ ID NO: 6)
[0117]
[0118] Reference Example 1. Production of Palbociclib-resistant breast cancer cell lines
[0119] 1.1. Preparation of palbociclib-resistant breast cancer cell line MCF7-PR
[0120] MCF7, a palbociclib-sensitive breast cancer cell line, was cultured. Then, palbociclib, a CDK4 / 6 inhibitor, was administered in gradually increasing concentrations for 8 months to generate MCF7-PR, a palbociclib-resistant breast cancer cell line.
[0121] Specifically, to generate a cell line resistant to palbociclib, a CDK4 / 6 inhibitor, using MCF7 cells, MCF7 cells were cultured in a cell culture medium containing palbociclib at a concentration of 750 nM, which is the IC50 concentration of palbociclib for MCF7. Thereafter, the cell culture medium containing palbociclib or the cell culture medium not containing palbociclib was alternately replaced every 3 days. During the process of culturing while replacing the culture medium, if cell proliferation in the cell culture medium containing palbociclib increased, the concentration of palbociclib was gradually increased while continuing the cell culture. Through the above process for 8 months, the cells began to acquire resistance to palbociclib, and when the IC50 became 10 times the initial value, it was determined that palbociclib resistance was acquired, and the generation of the MCF7-PR cell line, a palbociclib-resistant cell, was completed.
[0122]
[0123] 1.2. Preparation of palbociclib-resistant breast cancer cell line T47D-PR
[0124] A palbociclib-sensitive and -resistant cell line, T47D-PR, was prepared in the same manner as in Reference Example 1.1, except that T47D, a palbociclib-sensitive breast cancer cell line, was used.
[0125] Specifically, to generate a cell line resistant to palbociclib, a CDK4 / 6 inhibitor, using T47D cells, T47D cells were cultured in a cell culture medium containing palbociclib at a concentration of 250 nM, which is the IC50 concentration of palbociclib in T47D. Thereafter, the cell culture medium containing palbociclib or the cell culture medium not containing palbociclib was alternately replaced every 3 days. During the process of replacing the culture medium and culturing, if cell proliferation in the cell culture medium containing palbociclib increased, the concentration of palbociclib was gradually increased while continuing the cell culture. Through the above process for 8 months, the cells began to acquire resistance to palbociclib, and when the IC50 became 10 times the initial value, it was determined that palbociclib resistance was acquired, and the generation of the T47D-PR cell line, a palbociclib-resistant cell, was completed.
[0126]
[0127] Experimental Example 1. Confirmation of differences in gene expression in palbociclib-sensitive and -resistant cell lines.
[0128] Genes with differences in expression were identified through mRNA microassay in palbociclib-sensitive breast cancer cell lines MCF7 and T47D, and palbociclib-resistant breast cancer cell lines MCF7-PR and T47D-PR prepared in Reference Example 1 above. The results are shown in Fig. 1.
[0129] Figure 1 shows the results of mRNA microarray performed on palbociclib-sensitive breast cancer cell lines and palbociclib-resistant breast cancer cell lines.
[0130] As shown in Figure 1, the genes whose expression was statistically significantly different between palbociclib-sensitive and -resistant breast cancer cell lines were confirmed to be PEG10 (Paternally Expressed Gene 10) and EMT (Epithelial-Mesenchymal Transition)-related genes.
[0131]
[0132] Additionally, the expression of EMT-related proteins was confirmed through Western blot, and the results are shown in Figure 2.
[0133] Figure 2 shows the expression of EMT-related proteins confirmed by western blot in a palbociclib-resistant cell line.
[0134] As shown in Figure 2, increased expression of EMT-related proteins was confirmed in MCF7-PR and T47D-PR, which are palbociclib-resistant cell lines, by western blot.
[0135]
[0136] Experimental Example 2. Confirmation of Palbociclib Resistance Based on PEG10 Expression
[0137] The expression of PEG10, identified as a resistance-associated gene through Experimental Example 1, was controlled to analyze changes in the anticancer activity of palbociclib. To increase PEG10 expression, palbociclib-sensitive breast cancer cell lines MCF7 and T47D were transfected with a plasmid overexpressing PEG10 to artificially increase PEG10 expression. In addition, to decrease PEG10 expression, palbociclib-resistant cell lines MCF7-PR and T47D-PR were treated with PEG10 siRNA. Subsequently, the expression of EMT-related proteins was confirmed by western blot, and the anticancer activity of palbociclib was confirmed by MTT assay. The results are shown in Figures 3 to 6.
[0138] Figure 3 shows the expression of EMT-related proteins confirmed by western blot in palbociclib-sensitive hormone receptor-positive breast cancer cells transfected with a PEG10 overexpression plasmid.
[0139] Figure 4 shows the results of MTT assay to confirm the resistance to palbociclib in palbociclib-sensitive hormone receptor-positive breast cancer cells transfected with a PEG10 overexpression plasmid.
[0140] Figure 5 shows the expression of EMT-related proteins confirmed by western blot in palbociclib-resistant cells treated with PEG10 siRNA.
[0141] Figure 6 shows the degree of overcoming resistance to palbociclib in palbociclib-resistant cells administered with a combination of PEG10 siRNA and palbociclib, as confirmed by MTT assay.
[0142] As shown in Figures 3 and 4, when the expression of PEG10 was artificially increased by transfecting MCF7 and T47D with a PEG10 overexpression plasmid, it was confirmed that EMT-related proteins increased. In addition, when MCF7 and T47D cells with increased PEG10 expression were treated with palbociclib at various concentrations and the anticancer activity was confirmed using an MTT assay, it was confirmed that the anticancer activity of palbociclib decreased.
[0143] As shown in Figures 5 and 6, when PEG10 siRNA was treated to palbociclib-resistant cell lines MCF7-PR and T47D-PR, it was confirmed that EMT-related proteins were suppressed when PEG10 was inhibited. In addition, as a result of confirming anticancer activity using an MTT assay, it was confirmed that when PEG10 siRNA and palbociclib were co-administered to the same cell line, the anticancer activity increased compared to when palbociclib and PEG10 siRNA were administered alone.
[0144] From the above results, it was confirmed that resistance to palbociclib could be overcome by inhibiting PEG10.
[0145]
[0146] Experimental Example 3. Confirmation of the effect of PEG10 ASO treatment on CDK4 / 6 inhibitor-resistant breast cancer.
[0147] 3.1. Confirmation of PEG10 inhibition efficacy of PEG10 ASO
[0148] To confirm the efficacy of PEG10 ASO comprising sequences of SEQ ID NOs: 1 to 5 manufactured in Example 1, the inhibitory efficacy of PEG10 was confirmed in the MCF7-PR cell line using western blot and RT-PCR. The results are shown in Figures 7 to 10, and the results of Figure 7 are numerically presented in Table 2.
[0149] RF1 / 2 PEG10 expression in each ASO compared to sampleControl ASO RF1 PEG10 expression in each ASO compared to control ASO Control11ASO 10.761610.49144ASO 20.848570.46291ASO 30.790760.46643ASO 40.774490.53379ASO 51.192550.66534
[0150]
[0151] Figure 7 shows the degree of inhibition of ASO 1 to ASO 5 by PEG10 in the MCF7-PR cell line confirmed by western blot.
[0152] Figure 8 shows the degree of inhibition of ASO 1, 3, and 4 by PEG10 in the MCF7-PR cell line confirmed by western blot.
[0153] Figure 9 shows the degree of PEG10 inhibition of ASO 2 and ASO 5 in the MCF7-PR cell line confirmed by western blot.
[0154] Figure 10 shows the degree of inhibition of ASO 1, 3, and 4 by PEG10 in the MCF7-PR cell line, as measured by mRNA expression levels.
[0155] As shown in Table 2 and Figures 7 to 10, PEG10 ASOs 1 to 5 were confirmed to significantly inhibit PEG10 at both low concentrations (200 nmol) and high concentrations (500 nmol). In particular, ASOs 1, 3, and 4 were confirmed to have excellent inhibitory efficacy even at low concentrations.
[0156]
[0157] Among the ASOs demonstrating excellent efficacy, additional experiments were conducted using ASO 3 and ASO 4, which demonstrated excellent inhibitory efficacy even at the mRNA level. PEG10 inhibitory efficacy was confirmed at the protein and mRNA levels in the MCF7-PR cell line, and PEG10 protein inhibitory efficacy was also confirmed in the T47D-PR and PC3 prostate cancer cell lines. The results are shown in Figures 11 to 14.
[0158] Figure 11 shows the degree of inhibition of ASO 3 and ASO 4 by PEG10 in the MCF7-PR cell line confirmed by western blot.
[0159] Figure 12 shows the degree of inhibition of ASO 3 and ASO 4 by PEG10 in the MCF7-PR cell line as determined by mRNA expression level.
[0160] Figure 13 shows the degree of inhibition of ASO 3 and ASO 4 by PEG10 in the T47D-PR cell line using western blot.
[0161] Figure 14 shows the degree of inhibition of PEG10 at low concentrations (100 nmol) and high concentrations (500 nmol) of ASO 4 using western blot in PC3, a prostate cancer cell line.
[0162] As shown in Figures 11 to 14, excellent PEG10 inhibitory efficacy was confirmed at the protein and mRNA levels by ASO 3 and ASO 4, and PEG10 inhibition was confirmed in various cell lines. Furthermore, since the inhibitory efficacy of ASO 4 was confirmed to be superior to that of ASO 3, experiments were subsequently conducted using ASO 4.
[0163]
[0164] 3.2. Confirmation of the EMT inhibitory efficacy of PEG10 ASO
[0165] In Experimental Example 3.1, ASO 4, which was confirmed to have the highest PEG10 inhibition effect, was used to confirm the expression of EMT-related proteins through western blot, and the results are shown in Figure 15.
[0166] Figure 15 shows the expression of EMT-related proteins confirmed by western blot in palbociclib-resistant cells treated with PEG10 ASO.
[0167] As shown in Figure 15, it was confirmed that PEG10 and the EMT pathway were inhibited when ASO 4 was treated, thereby confirming that resistance to CDK4 / 6 inhibitors can be overcome.
[0168]
[0169] 3.3 Confirmation of the mechanism by which PEG10 ASO suppresses EMT and overcomes CDK4 / 6 inhibitor resistance through SIAH1 and p21 gene activation.
[0170] Based on the results confirmed through Experimental Example 3.2 above, treatment with PEG10 ASO increased the expression of SIAH1 and p21 proteins. Therefore, experiments were conducted to determine the specific mechanism. To determine the mechanism by which PEG10 regulates SIAH1 and p21, a co-immunoprecipitation (CO-IP) assay was performed, which measures protein-protein interaction. The results are shown in Figure 16.
[0171] Figure 16 shows the results of a CO-IP assay performed in the MCF7-PR cell line.
[0172] As shown in Figure 16, it was confirmed that PEG10 binds to SIAH1 and p21 and inhibits SIAH1 and p21 in a palbociclib-resistant cell line.
[0173]
[0174] For further confirmation, SIAH1 overexpression plasmids and p21 overexpression plasmids were transfected into MCF7-PR and T47D-PR cell lines to determine their effects on the EMT signaling pathway and cell cycle. The results are shown in Figures 17 and 18.
[0175] Figure 17 shows that the EMT signaling pathway was inhibited in MCF7-PR and T47D-PR cell lines transduced with SIAH1 and p21 overexpression plasmids, as confirmed by western blot.
[0176] Figure 18 shows the effect on cell cycle control confirmed by western blot in a CDK4 / 6 inhibitor-resistant cell line transduced with a p21 overexpression plasmid.
[0177] As shown in Figure 17, it was confirmed that the EMT signaling pathway was inhibited when SIAH1 overexpression plasmid and p21 overexpression plasmid were transduced.
[0178] As shown in Figure 18, it was confirmed that the cell cycle-related proteins CDK2, Cyclin E, Cyclin D1, and Cyclin A increased in the MCF7-PR cell line compared to the MCF7 cell line. In addition, it was confirmed that the cell cycle-related proteins decreased in the CDK4 / 6 inhibitor-resistant cell lines MCF7-PR and T47D-PR transfected with a p21 overexpression plasmid, similar to the case in MCF7-PR treated with PEG10 siRNA.
[0179] From the above results, it was confirmed that PEG10 ASO activates SIAH1 and p21 genes, and that the activation of SIAH1 and p21 genes is involved in the inhibition of EMT-related mechanisms and overcoming CDK4 / 6 inhibitor resistance.
[0180]
[0181] 3.4. Confirmation of the efficacy of PEG10 ASO in a CDK4 / 6 inhibitor-resistant xenograft model
[0182] The efficacy of PEG10 ASO was confirmed by creating a xenograft model in which a tumor was formed by transplanting the MCF7-PR cell line, a palbociclib-resistant cell line, into mice. The groups treated with control ASO, palbociclib, and PEG10 ASO 4 alone and the groups treated with a combination of palbociclib and ASO 4 were used. The experiment was conducted by administering the sample daily for 4 days and then administering the sample 3 times for 2 weeks. Thereafter, the efficacy was confirmed in tumor tissue, and the results are shown in Figs. 19 and 20.
[0183] Figure 19 shows the cancer growth inhibition effect confirmed in a CDK4 / 6 inhibitor-resistant xenograft model.
[0184] Figure 20 shows the tumor tissue of a CDK4 / 6 inhibitor-resistant xenograft model immunochemically stained to confirm the proliferation marker Ki67.
[0185] As shown in Figures 19 and 20, tumor growth was not significantly inhibited in the palbociclib monotherapy group, but was significantly inhibited in the PEG10 ASO 4 monotherapy and combination therapy groups. In addition, it was confirmed that the combination of PEG10 ASO 4 and palbociclib further inhibited tumor growth compared to the PEG10 ASO 4 monotherapy group.
[0186] In addition, as a result of analyzing Ki67, a cancer cell proliferation marker in tumor tissues, by immunochemical staining, the effect of inhibiting cancer cell proliferation by administration of palbociclib alone was hardly confirmed, but it was confirmed that cancer cell proliferation was significantly reduced in the PEG10 ASO 4 single treatment group or the combined treatment group.
[0187] From the above results, it was confirmed that PEG10 ASO has the effect of improving CDK4 / 6 inhibitor resistance by inhibiting PEG10 and EMT mechanisms, and that when PEG10 ASO and CDK4 / 6 inhibitor are used together, they exhibit excellent anticancer effects due to the synergistic effect.
Claims
1. An antisense oligonucleotide (ASO) comprising any one polynucleotide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5 capable of inhibiting the expression of PEG10 (Paternally Expressed 10).
2. In claim 1, The above ASO is an ASO that complementarily binds to PEG10.
3. In claim 1, The above ASO is an ASO having a length of 8 to 50 nucleotides.
4. In claim 1, The above ASO is an ASO that can inhibit a protein associated with the EMT (Epithelial-to-Mesenchymal Transition) mechanism.
5. In claim 1, The above ASO is an ASO that can increase the gene activity or protein expression of SIAH1 and p21.
6. A pharmaceutical composition for treating cancer comprising an expression or activity inhibitor of PEG10 (Paternally Expressed 10) as an active ingredient.
7. In claim 6, A pharmaceutical composition, wherein the inhibitor is any one selected from the group consisting of an antisense oligonucleotide (ASO), a small hairpin RNA, a small interfering RNA (siRNA), and a ribozyme that complementarily binds to the gene of PEG10.
8. In claim 6, A pharmaceutical composition, wherein the inhibitor is any one selected from the group consisting of a peptide, peptide mimetics, substrate analog, aptamer, and antibody that binds to a PEG10 protein.
9. In claim 6, A pharmaceutical composition, wherein the antisense oligonucleotide comprises any one polynucleotide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:
5.
10. In claim 6, A pharmaceutical composition, wherein the cancer is CDK (Cyclin Dependent Kinase) 4 / 6 inhibitor-resistant cancer.
11. In claim 10, A pharmaceutical composition, wherein the CDK4 / 6 inhibitor-resistant cancer is breast cancer.
12. In claim 6, A pharmaceutical composition wherein the above composition can be administered in combination with an anticancer agent.
13. In claim 12, A pharmaceutical composition, wherein the anticancer agent is at least one selected from the group consisting of a chemotherapy agent, a targeted anticancer agent, an immunotherapy agent, a CDK4 / 6 inhibitor, and a combination thereof.
14. In claim 12, A pharmaceutical composition wherein the above combination administration is administered simultaneously or sequentially.
15. A composition for diagnosing cancer resistant to a CDK4 / 6 inhibitor, comprising a preparation capable of measuring the expression or activity of PEG10.
16. A method for treating cancer, comprising administering to a subject in need thereof an effective amount of an expression or activity inhibitor of PEG10 (Paternally Expressed 10).
17. A method for diagnosing cancer resistant to a CDK4 / 6 inhibitor, comprising the step of measuring the expression or activity of PEG10 from a sample isolated from the subject.
18. Use of an expression or activity inhibitor of PEG10 (Paternally Expressed 10) for the manufacture of a pharmaceutical preparation for treating cancer.
19. Use of an inhibitor of expression or activity of PEG10 (Paternally Expressed 10) for diagnosing cancer resistant to CDK4 / 6 inhibitors.
Citation Information
Patent Citations
Method for controlling proliferation and apoptosis of carcinoma cell
JP2003093066A
